Literature DB >> 8877554

In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter-.

A L Barry, S D Brown, P C Fuchs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8877554     DOI： 10.1093/jac/38.2.324

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.

Authors:  Michelle M Butler; William A Lamarr; Kimberly A Foster; Marjorie H Barnes; Donna J Skow; Patrick T Lyden; Lauren M Kustigian; Chengxin Zhi; Neal C Brown; George E Wright; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

Review 5.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

6.  Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.

Authors:  F Trémolières; F de Kock; N Pluck; R Daniel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.